GetTopicDetailResponse(id=4aad4254e05, topicName=復(fù)發(fā)性濾泡性淋巴瘤, introduction=復(fù)發(fā)性濾泡性淋巴瘤, content=null, image=null, comments=4, allHits=1236, url=https://h5.medsci.cn/topic?id=42547, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=58919, tagList=[TagDto(tagId=58919, tagName=復(fù)發(fā)性濾泡性淋巴瘤)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1694675, encodeId=b4a616946e5ec, content=<a href='/topic/show?id=4aad4254e05' target=_blank style='color:#2F92EE;'>#復(fù)發(fā)性濾泡性淋巴瘤#</a>, objectTitle=HAEMATOLOGICA：PET-CT狀態(tài)對(duì)接受自體干細(xì)胞移植的復(fù)發(fā)性濾泡性淋巴瘤患者無(wú)進(jìn)展生存期的影響, objectType=article, longId=727501, objectId=ccafe275011b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccafe275011b, replyNumber=0, likeNumber=100, createdTime=2022-07-07, rootId=0, userName=chenwq18, userId=3b4729711287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccafe275011b, moduleTitle=HAEMATOLOGICA：PET-CT狀態(tài)對(duì)接受自體干細(xì)胞移植的復(fù)發(fā)性濾泡性淋巴瘤患者無(wú)進(jìn)展生存期的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ccafe275011b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1694674, encodeId=6fff16946e493, content=<a href='/topic/show?id=4aad4254e05' target=_blank style='color:#2F92EE;'>#復(fù)發(fā)性濾泡性淋巴瘤#</a>, objectTitle=Blood：CD19 CAR-T細(xì)胞免疫療法有助于難治性/復(fù)發(fā)性濾泡性淋巴瘤患者獲得持久的緩解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=72, createdTime=2019-08-17, rootId=0, userName=chenwq18, userId=3b4729711287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T細(xì)胞免疫療法有助于難治性/復(fù)發(fā)性濾泡性淋巴瘤患者獲得持久的緩解, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1694673, encodeId=4b0416946e3a8, content=<a href='/topic/show?id=4aad4254e05' target=_blank style='color:#2F92EE;'>#復(fù)發(fā)性濾泡性淋巴瘤#</a>, objectTitle=治療復(fù)發(fā)性濾泡性淋巴瘤的新療法, objectType=article, longId=113010, objectId=afe9113010c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe9113010c9, replyNumber=0, likeNumber=139, createdTime=2017-12-28, rootId=0, userName=chenwq18, userId=3b4729711287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe9113010c9, moduleTitle=治療復(fù)發(fā)性濾泡性淋巴瘤的新療法, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=afe9113010c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1694672, encodeId=374b16946e2e1, content=<a href='/topic/show?id=4aad4254e05' target=_blank style='color:#2F92EE;'>#復(fù)發(fā)性濾泡性淋巴瘤#</a>, objectTitle=2016ESMO臨床診療指南——新診斷和復(fù)發(fā)性濾泡性淋巴瘤的診斷、治療與隨訪發(fā)布, objectType=article, longId=78484, objectId=c96ee84848f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c96ee84848f, replyNumber=0, likeNumber=74, createdTime=2017-07-12, rootId=0, userName=chenwq18, userId=3b4729711287, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c96ee84848f, moduleTitle=2016ESMO臨床診療指南——新診斷和復(fù)發(fā)性濾泡性淋巴瘤的診斷、治療與隨訪發(fā)布, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c96ee84848f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
